Analysts' Top 5 Price Targets of February 23, 2026
Reading Time: 3 minutes
Guardant Health [US40131M1099] Leerink Partners reaffirms Outperform rating and raises the price target from $170 to $180 (75% upside potential) The move follows another strong business performance from the company. Guardant Health reported revenue of $281.3 million in the fourth quarter, representing a 39% growth compared to the previous year, and also raised its revenue guidance for the full year 2026 to $1.25-1.28 billion (consensus: approximately $1.24 billion). Analysts emphasize that Guardant has solidified its position as a leading provider...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
